Bioheng
OverviewSuggest Edit
Bioheng (also known as Nanjing Beiheng Biotech, 北恒生物) is a biopharmaceutical company that focuses on immunotherapy and gene therapy for treating cancer. It also provides a range of contract research services, including target screening and verification, pre-clinical studies, quality management, CRISPR-CAS9 gene editing, etc.
| Type | Private | |
| Founded | 2017 | |
| HQ | Nanjing, CN | Map |
| Website | bioheng.com |
Locations
Latest Updates
| Cybersecurity rating | A | More |
Bioheng Financials and Metrics
Summary Metrics
Founding Date | 2017 |
Bioheng total Funding | $14.8 m |
Bioheng latest funding size | $14.78 m |
Time since last funding | 2 years ago |
Bioheng investors | Decheng Capital |
Bioheng's latest funding round in February 2019 was reported to be $14.8 m. In total, Bioheng has raised $14.8 m
Bioheng Cybersecurity Score
Bioheng Online and Social Media Presence
Bioheng's Trends
Bioheng Frequently Asked Questions
When was Bioheng founded?
Bioheng was founded in 2017.
Who are Bioheng competitors?
Competitors of Bioheng include Aptus Clinical, Stamford Pharmaceuticals and Hubro Therapeutics.
Where is Bioheng headquarters?
Bioheng headquarters is located at Pukou District, Nanjing.
Where are Bioheng offices?
Bioheng has an office in Nanjing.
How many offices does Bioheng have?
Bioheng has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies